Story
Capricor Therapeutics Stock Soars on Oppenheimer Upgrade, Positive FDA Update

Shares of Capricor Therapeutics (NASDAQ:CAPR) surged 15.7% in trading on Tuesday following a stock upgrade from investment bank Oppenheimer. The analyst cited positive regulatory developments from the U.S. Food and Drug Administration (FDA) regarding the company's experimental treatment for Duchenne muscular dystrophy (DMD).
Analyst Cites Clearer Path to Approval
Oppenheimer analyst Leland Gershall upgraded Capricor from 'Perform' to 'Outperform' and initiated a price target of $54 per share. The upgrade was driven by a recent FDA update on the company's drug candidate, deramiocel.
Gershall noted that the FDA's actions suggest the agency may consider an approval based on an upper limb function indication. According to the analyst, this would align with the primary endpoint of the Phase 3 trial, for which he stated that "efficacy appears less equivocal than for cardiomyopathy." The analyst expects shares will continue to rise "as the market re-evaluates deramiocel’s approval prospects."
AdFDA Sets New Review Date
The FDA accepted new materials submitted by Capricor since a recent advisory committee meeting, classifying the submission as a major amendment. This action has set a new Prescription Drug User Fee Act (PDUFA) target date of November 22 for a decision on the treatment.
In a follow-up call mentioned by Oppenheimer, Capricor CEO Linda Marbán indicated the company plans to release 24-month data from its HOPE-3 open-label extension study ahead of the new PDUFA date. This data will be part of the ongoing information provided to the FDA for its review.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.